Adcock Ingram warns margins will remain under pressure despite latest SEP increase
The maker of Panado, Corenza C and Allergex declared a total annual dividend of 250c per share
Pharmaceutical manufacturer Adcock Ingram has warned investors that profit margins on its portfolio of medicines that are subject to government price controls will remain under pressure, despite the “top up” increase announced in July.
Health minister Joe Phaahla agreed to a rare mid-year price increase for private-sector medicine sales in July, allowing companies to raise the single exit price (SEP) of eligible products by up to 1.73%, on top of the 3.28% increase announced last December. The “top up” increase, which would take effect in September, was a welcome development but was still not enough to completely offset inflation, said Adcock Ingram CEO Andy Hall...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.